Laura R. Parham - Concepedia

Author

Laura R. Parham

GlaxoSmithKline (United States)ORCID

Also Known As

L R Parham, L.R. Parham, Laura Parham, Laura R Parham, Laura R. Parham, Laura Rae Parham

Publications

304

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)Research Triangle Park Foundation PAREXEL International (United States)GlaxoSmithKline (United Kingdom)Age UK

About

Laura R. Parham is an author at GlaxoSmithKline (United States) specializing in medicine, immunology, and ophthalmology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	74
2	Hepatology	1	1	20
3	Immunology	1	1	54
4	Pathology	1	1	20
5	Pharmacology	1	1	20

Laura R. Parham

Publications

298

Citations

H-Index

Page 1

	Year	Citations
Prospective Validation of <i>HLA-DRB1</i>*<i>07:01</i> Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury Daniel J. Schaid, Colin F. Spraggs, Shannon K. McDonnell, Journal of Clinical Oncology	2014	75
Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01 Laura R. Parham, Linda P. Briley, L Li, The Pharmacogenomics Journal	2015	60
A Randomized Phase 2 Study of an Anti–Amyloid β Monoclonal Antibody in Geographic Atrophy Secondary to Age-Related Macular Degeneration Philip J. Rosenfeld, Brian B. Berger, Elias Reichel, Ophthalmology Retina Ocular DiseaseAlzheimer's DiseaseOphthalmologyAge-related DiseasesImmunology	2018	54
Lapatinib-Induced Liver Injury Characterized by Class II HLA and Gilbert's Syndrome Genotypes Colin F. Spraggs, Laura R. Parham, Christine M. Hunt, Clinical Pharmacology & Therapeutics	2012	50
Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis Lynn D. Condreay, Laura R. Parham, Xiaoyan A. Qu, Rheumatology International	2020	28
Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes Colin F. Spraggs, Laura R. Parham, Linda P. Briley, The Pharmacogenomics Journal Breast OncologyHepatologyMedicineLiver PhysiologyLapatinib-induced Liver Toxicity	2017	20
Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir Parul Patel, Zhengyu Xue, Karen S. King, Journal of Antimicrobial Chemotherapy	2020	11

Page 1